BridGene Biosciences’s IMTAC™ Platform is a proprietary Chemoproteomic platform to develop potential therapies for high-value but previously undruggable targets, including targets involving protein-protein interactions or containing shallow binding pockets. It combines cutting-edge technologies including covalent chemistry, chemical proteomics, and quantitative mass spectrometry. It enables covalent small molecules to perform proteome-wide screening in live cells, which results in highly selective small molecules that drug traditionally undruggable targets.

IMTAC™ platform has the following key components:

• Proprietary proteome-trained and drug-like covalent small molecule library.
• Live-cell and proteome-wide screening to identify undruggable targets that interact with the small molecules.
• Mass Spec analysis to quantify the small molecules’ binding affinity against targets across the entire proteome, and ensure the precise selectivity of the small molecules.
• Proprietary novel small molecule ligands for thousands of human proteins.